3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Withdrawn
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Leukemia, Myeloid, Acute
12
Multiple Myeloma
11
Recurrence
8
Lymphoma, Large B-Cell, Diffuse
4
Sarcoma
3
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Endometrial Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neoplasms, Plasma Cell
2
Myelodysplastic Syndromes
2
Melanoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, B-Cell
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Congenital Abnormalities
2
Colorectal Neoplasms
2
Waldenstrom Macroglobulinemia
1
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Sarcoma, Endometrial Stromal
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Interventions
Doxorubicin
14
Radiotherapy
10
Ifosfamide
10
Trabectedin
7
pazopanib
4
Imatinib Mesylate
3
Filgrastim
3
Etoposide
3
Cyclophosphamide
3
Chemotherapy, Adjuvant
3
temsirolimus
2
romidepsin
2
ribociclib
2
pegfilgrastim
2
eribulin
2
cixutumumab
2
brigimadlin
2
belinostat
2
Vincristine
2
Sunitinib
2
Radiotherapy, Conformal
2
Gemcitabine
2
Epirubicin
2
Dexamethasone
2
Dactinomycin
2
Carboplatin
2
soblidotin
1
sitravatinib
1
siremadlin
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Liposarcoma
×
selinexor
×
Clear all
NCT02606461
2023-01-23
SEAL
Karyopharm Therapeutics Inc
Phase 2/3
Completed
342 enrolled
36 charts